News Daxor Corporation

Equities

DXR

US2394671034

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
9.65 ^USD	-2.92%		-1.03%	+0.52%

Apr. 16	Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	CI
Apr. 10	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	Apr. 16	AQ
Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	Apr. 16	CI
Daxor Corporation to Exhibit at the Medaxiom Cardiovascular Transforum Conference Spring'24 to Advance Awareness and Further Adoption of Daxor's Blood Volume Diagnostic	Apr. 16	AQ
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)	Apr. 15	AQ
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	Apr. 10	AQ
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	Apr. 10	CI
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24	Apr. 01	AQ
Transcript : Daxor Corporation, 2023 Earnings Call, Mar 25, 2024	Mar. 25
Daxor to Acquire Volumex, Megatope to Increase Diagnostics Suite	Mar. 25	MT
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics	Mar. 25	AQ
Daxor Corporation has entered into a definitive agreement to acquire Volumex®, Megatope® and Glofil® from Iso-Tex Diagnostics, Inc.	Mar. 24	CI
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024	Mar. 22	AQ
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023	Mar. 18	AQ
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders	Mar. 18	AQ
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	Mar. 11	AQ
Daxor Corporation Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	Mar. 11	CI
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients	Mar. 08	AQ
Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis	Mar. 08	CI
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference	Feb. 26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Daxor Corporation

Equities

DXR

US2394671034

Summary

Filters